Table 4. Association of the smoking status, lesion subtype and baseline BCVA with CSMT change at month 6.
|
Potential variables |
p values |
|||
|
Smoking status |
Never smoked |
Ex-smokers |
Current smokers |
|
| Number of cases |
41 |
17 |
44 |
|
| Mean baseline CSMT |
268.27±64.85 |
293.35±76.82 |
299.23±93.68 |
0.53/ 0.18 |
| Mean CSMT decrease |
39.07±69.27 |
93.88±71.76 |
71.66±103.91 |
0.08/0.20 |
|
Lesion characteristics |
Typical nAMD |
PCV |
|
|
| Number of cases |
70 |
32 |
|
|
| Mean baseline CSMT |
282.34±79.04 |
293.38±85.71 |
0.526 |
|
| Mean CSMT decrease |
50.53±92.29 |
80.06±105.10 |
0.051 |
|
|
Baseline visual acuity |
<20/100 |
20≥100 |
|
|
| Number of cases |
55 |
47 |
|
|
| Mean baseline CSMT |
292.39±78.87 |
278.10±83.47 |
0.38 |
|
| Mean CSMT decrease | 66.04±81.29 | 57.85±95.90 | 0.64 | |
Never smoked is the reference category (one-way ANOVA). CSMT=central subfield macular thickness (µm); nAMD=neovascular age-related macular degeneration; PCV=polypoidal choroidal vasculopathy